Under construction – not a live service
Sign in
Taking people in IndiaPhase 2

Tests adjusting radiation doses for brain tumors using artificial intelligence

Tests adaptive radiotherapy, guided by scans and AI, in adults with glioma.

Key facts

Who runs it
Tata Memorial Centre
Where
Mumbai, IndiaSee the site
Trial code
Registry title
Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow
Status
Recruiting
Phase
Phase 2
People taking part
60 people, planned
Started
27 Jul 2026
Expected to end
30 Jul 2028
Type of study
Interventional, 2 groups
Treatments tested
  • Adaptive radiotherapy
Record updated
17 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a diffuse glioma, a brain tumor, who need radiotherapy. Radiation doses will be adjusted using scans and artificial intelligence.

Age
18-70 years
Sex
All sexes can join.
Disease stage
Diffuse glioma confirmed by tissue examination. Either IDH-negative glioblastoma, or IDH-mutant glioma (astrocytoma or oligodendroglioma), that needs radiotherapy.
Earlier treatment
People who had earlier radiotherapy to the head, neck or brain, or earlier chemotherapy, cannot join.
Biomarker or test result
IDH status must be known and readable (by IHC or gene sequencing). Either IDH-negative or IDH-mutant.

Main reasons for not taking part

  • Tumor in more than one place in the brain (multifocal or multicentric disease)
  • Not able to have radiation with radical intent
  • IDH status unknown or not readable
  • Earlier radiotherapy to the head, neck or brain, or earlier chemotherapy
  • Cannot have MRI or PET scans during radiation

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Histological diagnosis of diffuse glioma. Patients with IDH-negative GBM (stratum A) and IDH-mutant glioma (astrocytoma or oligodendroglioma) need radiotherapy (stratum B); Age: 18-70 years. Karnofsky Performance Scale (KPS) ≥60

Who cannot take part

  • Multifocal or multicentric disease Not eligible for radical intent radiation. IDH status is unknown or uninterpretable (IHC or gene sequencing). Use of prior radiotherapy to the head-neck region or brain or chemotherapy. Contraindication/unable to undergo MRI or PET scan during radiation

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Where in India

  • Tata Memorial HospitalMumbai, IndiaContact: Archya Dasgupta, MDTaking people

About the trial

What the trial wants to find out

Gliomas are common primary brain tumors in adults. Gliomas can be classified into different types based on tumor grade, histopathological features, and molecular characteristics. The common types of diffuse gliomas include glioblastoma, astrocytoma, and oligodendroglioma. The standard treatment for diffuse gliomas includes surgery followed by radiation and chemotherapy. As per standard institutional practice, a uniform dose of radiation is delivered to the disease area and MRI is done before and after the treatment. In this study, MRI and PET scan will be done before starting the treatment and standard dose of radiation will be delivered. The interval imaging will be done twice during the course of treatment with MRI and PET, followed by dose modifications. The CT, MRI, and PET will be combined. Based on PET imaging, specific dose will be altered and delivered to specific areas. Dose modification will be done with the help of artificial intelligence. Participant's assessment will be done at regular intervals.

Read full original descriptionShow less

Modifications in radiation plans are done based on the changes in disease seen in scans is likely to improve the accuracy of RT treatments. Dose modifications based on imaging to resistant areas will help achieve better tumor control, reduce treatment-related toxicities, precise delivery of the RT and adjusting doses to the organs at risk (OAR) and changes in disease leading to better treatment compliance. Creating an artificial intelligence framework in radiation oncology promises to improve quality of workflow, treatment planning and RT delivery.

The aim of the study is to develop an artificial intelligence workflow for treatment of glioma with adaptive radiotherapy. This study will be conducted in Tata Memorial Centre on a population of 60 patients for a duration of 2 years. The total study duration is 4 years.

The 2 groups in the trial

  • Stratum A (IDH-negative GBM)Treatment being tested

    Adaptive radiotherapy

    Treatment: Adaptive radiotherapy

  • Stratum B (IDH-mutant astrocytoma or oligodendroglioma)Treatment being tested

    Adaptive radiotherapy

    Treatment: Adaptive radiotherapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow
Plain-language title
Tests adjusting radiation doses for brain tumors using artificial intelligenceGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06492486, who can take part
Record updated
17 August 2026